Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Taylor Morrisette

Showing results (71-80 of 76) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 76 results.
Open Forum Infectious Diseases|August 25, 2021
Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant <i>Enterobacterales</i> and <i>Pseudomonas aeruginosa</i>Sara Alosaimy, Abdalhamid M Lagnf, Taylor Morrisette, et al.
Microbiology Spectrum|August 26, 2025
Eravacycline use in immunocompromised patients: multicenter evaluation of timely versus late initiation on clinical outcomesAshlan J Kunz Coyne, Sara Alosaimy, Kristen Lucas, et al.
Antimicrobial Agents and Chemotherapy|September 28, 2023
Long-term evaluation of clinical success and safety of omadacycline in nontuberculous mycobacteria infections: a retrospective, multicenter cohort of real-world health outcomesAmer El Ghali, Taylor Morrisette, Sara Alosaimy, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 19, 2022
Nephrotoxicity of Vancomycin in Combination With Beta-Lactam Agents: Ceftolozane-Tazobactam vs Piperacillin-TazobactamSara Alosaimy, Abdalhamid M Lagnf, Athena L V Hobbs, et al.
Microbiology Spectrum|November 29, 2023
Eravacycline, the first four years: health outcomes and tolerability data for 19 hospitals in 5 U.S. regions from 2018 to 2022Ashlan J Kunz Coyne, Sara Alosaimy, Kristen Lucas, et al.
Antimicrobial Agents and Chemotherapy|May 15, 2026
Ceftazidime-avibactam for multidrug-resistant gram-negative infections: outcomes and timing of initiation across 22 U.S. medical centersAshlan J Kunz Coyne, Chloe Judd, Kristen Lucas, et al.
Pageof 8

Showing results (71-80 of 76) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 76 results.
Open Forum Infectious Diseases|August 25, 2021
Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant <i>Enterobacterales</i> and <i>Pseudomonas aeruginosa</i>Sara Alosaimy, Abdalhamid M Lagnf, Taylor Morrisette, et al.
Microbiology Spectrum|August 26, 2025
Eravacycline use in immunocompromised patients: multicenter evaluation of timely versus late initiation on clinical outcomesAshlan J Kunz Coyne, Sara Alosaimy, Kristen Lucas, et al.
Antimicrobial Agents and Chemotherapy|September 28, 2023
Long-term evaluation of clinical success and safety of omadacycline in nontuberculous mycobacteria infections: a retrospective, multicenter cohort of real-world health outcomesAmer El Ghali, Taylor Morrisette, Sara Alosaimy, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 19, 2022
Nephrotoxicity of Vancomycin in Combination With Beta-Lactam Agents: Ceftolozane-Tazobactam vs Piperacillin-TazobactamSara Alosaimy, Abdalhamid M Lagnf, Athena L V Hobbs, et al.
Microbiology Spectrum|November 29, 2023
Eravacycline, the first four years: health outcomes and tolerability data for 19 hospitals in 5 U.S. regions from 2018 to 2022Ashlan J Kunz Coyne, Sara Alosaimy, Kristen Lucas, et al.
Antimicrobial Agents and Chemotherapy|May 15, 2026
Ceftazidime-avibactam for multidrug-resistant gram-negative infections: outcomes and timing of initiation across 22 U.S. medical centersAshlan J Kunz Coyne, Chloe Judd, Kristen Lucas, et al.
Pageof 8